Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10681465 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL10504563 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL544481 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL6734265 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| Hydrochloric Acid SCHEMBL14742972 | 0.98 | LTA4H (0.37) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL2948327 | 0.90 | ALOX15 (0.35) | HRH3HRH2HRH1 | |
| SCHEMBL2210788 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10505725 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10505714 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| SCHEMBL2110831 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263548-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025021943-A1 | QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NEURALIS (BE) | 2025-01-30 | — | — | WO | disclosed |
| EP-4376845-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-5034402-A | Cerebral insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0212588-B1 | Saturated cycloalkyl [b] pyrrole-1(2H)-acetic acid amides and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0174136-B1 | DERIVATIVES OF DIHYDRO-1H-PYRROLO(1,2-C)IMIDAZOL-3,5-DIONE AS COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY (US) | 1989-03-22 | — | — | EP | disclosed |
| US-4758585-A | Saturated cycloalkyl (B) pyrrol-1 (2H)- acetic acid amides and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1988-07-19 | — | — | US | disclosed |
| US-4650878-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0212588-A1 | Saturated cycloalkyl [b] pyrrole-1(2H)-acetic acid amides and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4582838-A | FOR TREATING SENILITY OR REVERSING EFFECTS OF ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA | WARNER-LAMBERT COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0174136-A1 | Derivatives of dihydro-1H-pyrrolo(1,2-c)imidazol-3,5-dione as cognition activators | WARNER-LAMBERT COMPANY (US) | 1986-03-12 | — | — | EP | disclosed |
| US-4476308-A | 1-Pyrrolidine acetamides | HOFFMANN-LA ROCHE INC. (US) | 1984-10-09 | — | — | US | disclosed |
| US-4145347-A | TREATMENT OF SENILITY, AMNESIA AND LEARNING DISORDERS | PARKE, DAVIS & COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | LTA4H 488/4885HRH3 512/4885HRH2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.